Abstract:Human epidermal growth factor receptor 2 (HER2) is an orphan receptor tyrosine kinase member of the EGFR families and is found to be a key tumor driver gene. In breast cancer and gastric cancer, HER2 amplification can be effectively treated by its neutralizing antibody, trastuzumab. In clinic, the HER2 immunohistochemistry (IHC) was used as the primary screening method to diagnose HER2 amplification. However, recent evidence suggested that the frequently used rabbit HER2 antibody 4B5 cross reacted to another family member HER4. IHC staining also indicated that it has strong non-specific cytoplasmic and nucleus staining in normal gastric mucosal cells and some gastric cancer samples. Using a protein lysate array which covers 85% of the human proteome, we have successfully identified and confirmed that the 4B5 bound to HER4 and a nuclear protein ZSCAN18 besides HER2. The non-specific binding accounts for the unexpected cytoplasmic and unclear staining of 4B5 on normal gastric epithelium. Finally, we have developed a novel HER2 mouse monoclonal antibody UMAB36 with similar sensitivity to 4B5 but only reacted to HER2 across the 17,000 proteins on the protein chip. In 129 breast cancer and 158 gastric cancer samples, UMAB36 showed 100% sensitivity and specificity comparing to the HER2 FISH reference results with no unspecific staining in the gastric mucosa layer. UMAB36 could provide an alternative high specific IHC reagent for HER2 amplification testing in gastric cancer population. Citation Format: Lixin Zhou, Kehu Yuan, Fangfang Ren, Lili Qi, Zhongwu Li, Guiyin Wu, Xiaozheng Huang, Yi Shen, Min Zhao, Wei Fu, Huibo Liu, Boyang Chu, Guangli Wang, Youmin Shu, Donghui Ma, Wei-Wu He, Jian Chen. Using protein chips to develop a highly specific HER2 antibody for HER2 amplification testing. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3399. doi:10.1158/1538-7445.AM2015-3399

Selection, Purification, and Characterization of a HER2-targeting Soluble Designed Ankyrin Repeat Protein by E. Coli Surface Display Using HER2-positive Melanoma Cells

Efficient Evolved Antibody Mimetic Designed Ankyrin Repeat Proteins Against Programmed Death-Ligand 1 on E. Coli Surface Display

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

Peptidomimetic-based antibody surrogate for HER2

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Selective Cytotoxicity to HER2-Positive Tumor Cells by a Recombinant E23sfv-Td-tbid Protein Containing a Furin Cleavage Sequence

Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain

Selective staining and eradication of cancer cells by protein-carrying DARPin-functionalized liposomes

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.

Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo

Expression and Characterization of Recombinant Humanized Anti-Her2 Single-Chain Antibody in Pichia Pastoris for Targeted Cancer Therapy

Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization

Anti-Human Epidermal Growth Factor Receptor 2 Single-Chain Fv Fragment-Decorated DM1 Nanoparticles for Specific Targeting of Human Epidermal Growth Factor Receptor 2-Positive Breast Tumor Cells.

High Level Expression and Characterization of the Recombinant Immunotoxin DAB389-4D5 Scfv Targeting HER2/neu-positive Ovarian Carcinoma Cells

Targeted Delivery of HSP70 to Tumor Cells via Supramolecular Complex Based on HER2-Specific DARPin9_29 and the Barnase:Barstar Pair

A novel HER2-specific sensor based on DARPin_9-29 and albumin binding domain for real-time fluorescence-guided tumor detection in animal model of cancer

Manufacture and Evaluation of a HER2-positive Breast Cancer Immunotoxin 4D5fv-Pe25

Abstract 3399: Using Protein Chips to Develop a Highly Specific HER2 Antibody for HER2 Amplification Testing

Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development

Bivalent EGFR-Targeting DARPin-MMAE Conjugates

Rational Design and Construction of HER2 Targeting Recombinant Human Serum Albumin